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Abstract
A novel complex formed by ruthenium (111) and the sequestering ligand 1,2-
propylenediaminetetraacetic acid (PDTA) has been synthetized and characterized. The structure
of the monomeric compound, studied by X-ray diffraction, shows an almost symmetric octahedral
geometry around the metal ion, with two chlorine atoms in a cis conformation. The antitumour
activity against a variety of murine and human cancers is reported.
Introduction
Many compounds of transition metals with 1,2-propylenediamine-N,N,N’,N’-tetraacetic
acid (PDTA, Figure 1), have been studied in recent years, although those formed by ruthenium
have been object of scarce attention(I-4). Compounds formed by this chelating agent, a methyl
derivative of EDTA, are of about two orders of magnitude more stable than the analogs formed with
the parent ligand. Furthermore, ruthenium complexes with PDTA may be of interest because of
the easy conversion of this element from one oxidation state into another at the appropriate
experimental conditions, and because of the tendency of its compounds to undergo hydrolysis.
Advantage can be taken from the ready availability of both the Ru(lll) and Ru(ll) oxidation states
under physiological conditions and the general inertness of these ions toward substitution, when
coordinated to nitrogen ligands(5). All the referred properties are in close connection to the ability
of the ruthenium complexes to act as potential antitumour drugs(6-9).
H2 H2
HOOC C C COOH
\ /
N-----CH---C- N
HOOC C CH3 C COOH
H2 H2
Figure 1. Schematic structure of the ligand PDTA
Ruthenium complexes with polydentate chelating agents ("secondary ligands") may be
considered as prodrugs against different tumors. The role of the secondary ligand is to stabilize
the ruthenium (111) cation so that the metal is not delivered to the tissues during its transportation in
the body and the whole complex remains unchanged. In this way, a drastic lowering of the host
toxicity produced by these potential drugs have been observed. Once the complex reaches the
hypoxic areas proper of tumor tissues, the metal ion is reduced "in situ", this feature promoting the
accumulation of ruthenium in tumor masses(10,11). As published(10), a PDTA-Ru(III) complex
accumulates in tumor tissues (female Swiss mice bearing EMT-6 solid sarcoma) in higher
proportion (TCI 2.13) than other ruthenium compounds, i.e., TCI 1.70 for Ru(en)2CI2 (TCI
tumor concentration index % of inyected doses per g of tumor/% inyected doses per g of total
weight). At the same time, the rate drug dose/g of tissue of PDTA-Ru drug found in liver and
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kidneys is much lower (2.30 and 5.42 %) than in the Ru(en)2CI2 compound (5.76 and 11.15 %). It
has been proposed that the "primary ligands" (i.e., chlorine atoms or sulfate, nitrate, carbonate,
oxalate, malonate anions) are replaced by nitrogen or oxygen atoms from the nucleobases of
cellular DNA, purine and pyrimidine bases, if the DNA is the macromolecular target of these
complexes(5). Research in progress evidences that this type of metal drugs interferes in the
growing process of human mammary carcinomas(12).
In the present paper, we characterize and isolate in crystalline form a new compound of
Ru(lll) with PDTA. The study of the properties employs the use of chemical analyses,
potentiometry, vibrational spectroscopy and X-ray diffraction structural studies. The obtained data
made it possible to reach conclusions about the strength of the bonds formed by ruthenium with
nitrogen and oxygen atoms of the chelating ligand and also with the chlorine atoms directly
bonded to the metal ion. Finally, the activity of the new potential drug against different
experimental and human tumors has been tested "in vivo".
Materials and Methods
Chemicals
Hydrated ruthenium (111) chloride was used as provided by Johnson Matthey. All chemicals
obtained from commercial suppliers were used without further purification. Water of Millipore
quality was used in all solutions.
Elemental analyses
Elemental microanalyses were performed at the Analytical Chemistry Department of the
Sevilla University. Hydration water was determined by Karl-Fischer titrimetry. Metal content was
determined by atomic absorption spectroscopy using a Perkin Elmer 2380 model, at 10 mA and
of 349.9 rim.
Titrimetry
Potentiometric measurements were carried out using a Crison MicroTT 2022 titrimeter,
provided with autoburette Microbur 2030. Aqueous solutions of the complex (30-60 rag/100 mL)
were titrated against NaOH 29.5 mM solution. Electrical conductimetry of the same solutions were
performed using a Crison 525 conductimeter.
Spectroscopic and magnetic studies
Infrared spectra were recorded on Perkin Elmer 883 (4000-400 cm-1 range) and FT-IR
16PC (400 200 cm1 interval) instruments, respectively. The spectra in the 4000-400 cm-1 range
were taken as KBr discs, while far-infrared spectra were measured as Nujol mulls supported
between polyethylene sheets. Electronic spectra were taken with a Jasco V-550 spectrometer
while magnetic measurements were carried out in a Faraday type equipment equipped with helium
cryostat at temperatures between 70 and 300K. The balance was calibrated with standard
Hg[Co(SCN)4]. Pascal Tables were used for diamagnetic corrections.
Antitumor essays
The cytotoxic effect of the ruthenium compound has been evaluated against Ehrlich
ascitic tumor (EAT) and the murine or human carcinomas: limphocytic L1210 and P388 leukemias,
M5076 intraperitoneal implanted sarcoma, and MX-1 human transplanted mammary sarcoma. Most
of the experiments were performed at NIH, Bethesda, USA and ONC, Madrid, Spain.
X-ray diffraction
A brown, irregular prismatic crystal, dimensions 0.1 x 0.2 x 0.3 mm was mounted in a Stoe-
Siemens AED 2 diffractometer with MoKa radiation (Z, 0.71073 A). A total of 5898 independent
reflections were measured in the range -26 _< h _< 26, -10 <_ k _< 10, -20 _<1 _< 20, 20 < 60, 4947 with
F > 4G(F) retained for structure solution and refinement. Data were corrected for Lorentz and
polarisation and absorption (empirically, Z scans, transmission range, 0.623-0.781). Ruthenium
and chlorine atoms were located from a Patterson map, other atoms from successive/F maps. The
structure was refined anisotropically for non-H atoms, minimizing Zw(Fo-Fc)2 with w-1 G2(F) +
0.001 F2.
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Table 1. Atomic coordinates (Ru and CI, x105; other, xl04)
and equivalent isotropic displacement coefficients (.&.2x103)
x y z U(eq)
Ru 7521(3) 14272(3) 0 24.87(6)
C1(1) 4013(6) 28254(18) -13788(8) 43.1(3)
C1(2) 17342(6) 149(17) -7310(8) 43.4(3)
C(1) 596(2) 1449(5) 1976(3) 29(1)
C(2) -167(2) 1446(5) 1634(3) 28(1)
C(3) -665(2) 2279(7) 2352(3) 41 (1)
N(1) 1097(2) 555(4) 1311(2) 26(1)
C(11 1840(2) 1285(6) 1427(3) 34(1
C(12) 1901(2) 3070(6) 932(3) 31(1)
O(11) 1415(2) 3472(4) 366(2) 33(1)
O(12) 2427(2) 4049(5) 1103(2) 44(1
C(13) 1068(2) -1417(5) 1375(3) 30(1)
C(14) 1310(2) -2223(6) 2271(3) 33(1)
O(13) 1591(2) -1413(4) 2898(2) 47(1)
O(14) 1179(2) -3953(4) 2293(2) 43(1
N(2) -193(2) 2339(4) 698(2) 25(1)
C(21) -801(2) 1568(5) 155(3) 30(1)
C(22) -592(2) -250(5) -232(3) 29(1)
O(21) 77(1) -636(4) -277(2) 32(1)
0(22) -1063(2) -1297(4) -504(2) 42(1)
C(23) -201 (2) 4323(5) 717(3) 30(1
C(24) -885(2) 5260(5) 1022(3) 31(1)
0(23) -1488(2) 4717(5) 890(3) 57(1)
0(24) -733(2) 6803(4) 1408(3) 40(1
O(lW) 1820(2) 1485(5) -2806(3) 52(1)
O(2W) 2592(2) 6017(6) -334(3) 63(1)
O(3W) 1919(2) 4882(6) -1674(3) 62(1
O(4W) -1542(3) -4486(7) -1224(4) 86(2)
Equivalent isotropic U defined as one third of the trace of the orthogonalized Uij tensor
Hydrogen atoms attached to carbon were idealized whereas those attached to oxygen were
located in AF maps and refined with fixed O-H distances (0.85 A). Final residues were R 0.033,
Rw 0.033, S 1.02, -1.39 < AF < 0.91 e./,-3, shift/ below 0.001 in the last cycle. Final atomic
coordinates are included in Table 1, hydrogen coordinates, anisotropic thermal parameters are
included in the supplementary material. Tables of structure factors are available from the authors
on request.
Synthesis of the compound [RuLCI2]H.4H20 (L = PDTA)
A solution of RuCl3.xH20 (0.50 g, 2.0 mmol) in 200 ml of HCl 0.1 M is introduced in a 500
ml round-bottom flask and 0.62 g of solid PDTA is carefully added on the ruthenium solution while
stirring. The mixture is magnetically stirred for about 10 minutes. The flask is air-tight sealed and
heated for about 12 hours at 130 -C in an electric oven. Along this time, all the ligand is dissolved
and the initial dark-red colour of the mixture changes to pale-purple colour. After cooling at room
temperature, the solution is filtered and slowly evaporated in water-bath at 70-C until small volume
(i.e, 10 ml). Red-brown prismatic crystals are recovered after filtration from the mother liquor. Anal.
Calcd. for C11H24012N2C12Ru: C, 24.05; H, 4.59; N, 5.10; Cl 12.9; Ru, 18.4; M+ 548.3. Found:
C, 24.2; H, 4.29; N, 5.19; Cl, 12.9; Ru, 18.3; M+ 549.
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Figure 2" Molecular structure of [RuLCI2]H.H20
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Figure 3: Stereoview of the unit cell packing diagram for [RuLCI2]H.H20
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Results and Discussion
Isolation of the ruthenium (111) complex
The synthesis of the title complex is performed in a molar metal/ligand ratio of 1/1 and the
reaction takes places in a sealed flask at 130-C. In the conditions explained in the experimental
section, a yield of 72.3 % is obtained. The solid is extremely soluble in water and stable to air at
room temperature.
Crystallographic studies
A view of the anion dichloro(propylendiaminetetraacetato) ruthenate(lll) is shown in Figure
2. Crystal and refinement data for [RuLCI2]H.4H20 are summarized in Table 2. Bond distances and
angles are indicated in Table 3. The metal atom is octahedrally coordinated by two chlorine atoms,
placed in cis positions and the organic ligand occupying the remaining four vertexes of the
octahedron via the two nitrogen atoms (trans to chlorines) and two carboxylate groups, closing
three five-membered chelate rings. The non-coordinated carboxylic acid groups are clearly
protonated, as can be seen from the corresponding C-O distances and the hydrogen bond
scheme, the attached hydrogen atoms readily located in difference Fourier maps. The structure of
this complex ion is similar to the analogous with EDTA and very close to the one with DCTA(6,9), a
difference being that the distances Ru-CI are more similar to each other in the PDTA compound.
As in the DCTA complex, Ru-CI bond distances [2.361(1) A and 2.362(1)A] are much longer than
the reported in literature for similar compounds(4,13), this fact contributing to enhance the labile
character of the halide ligands. The equal distances found for the Ru-O bonds indicate the
absence of tetragonal distortion. A noteworthy difference between the PDTA and DCTA
complexes of ruthenium is found considering the magnitude of the angles around the ruthenium
atom; these angles are not far away from ideal octahedral geometry in the PDTA complex, with the
logical closing of the N-Ru-O angles inside the chelate rings and the opening of their
supplementaries.
Table 2. Crystallographic data for [RuLCI2] H.4H20
Formula C11H24N2012CI2Ru
Molecular weight 548.3
Crystal system orthorhombic
a(,&,) 18.571(3)
b(,,) 7.464(1)
c(/) 14.617(3)
V(/&,3) 2026.2(8)
Space group Pna21
Z 4
Dcalc (g cm"3) 1.797
F(000) 1 1 12
X (MoKo0 (,&,) 0.71073
# (aoK(z) (mm"1) 1.099
Reflections measured 5898
R (= Rw) 0.033
All water molecules and the carboxylic acid groups act as donors in hydrogen bonding
(see Table 3), the acceptors being water molecules, carboxylate groups and chlorine atoms. A
view of some of these hydrogen bonds is displayed in Figure 3.
The oxidation state of ruthenium is +3, as shown by magnetic measurements, so an extra proton
must be attached to any of the water molecules in order to balance the charge of the complex
anion. Nevertheless, difference maps and the hydrogen bonds displayed in Table 3 let us to
identify clearly only two hydrogen atoms per water oxygen, the remaining proton being probably
disordered among water molecules.
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Ru-Cl(1)
Ru-Cl(2)
Ru-N(1)
Ru-O(11
Ru-N(2)
Ru-O(21)
C(1)-C(2)
C(1)-N(1)
C(2)-C(3)
C(2)-N(2)
N(1)-C(11)
N(1)-C(13)
C(11)-C(12)
C(12)-O(11
C(12)-O(12)
C(13)-C(14)
C(14)-O(13)
C(14)-O(14)
N(2)-C(21)
N(2)-C(23)
C(21)-C(22)
C(22)-O(21)
C(22)-O(22)
C(23)-C(24)
C(24)-O(23)
C(24)-O(24)
Hydrogen bonds:
O(14)---->O(4W)!.
O(24)--->O(lW)
O(lW)---C1(2)
O(lW)O(12)
O(2W)O(12).
O(2W)--->O(22)v
O(3W)-->O(2W)
O(3W)-->C1(1)
O(4W)--->O(22)
O(4W)--->C1(2)v
-x,-y-1 ,z+ 1/2
-x,-y+l ,z+ {-
-..--,- ,--
IVx+ ,-y+,z
V x- ,-y+ ,z
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Tabl 3. Interatomic distances (A) and bond angles (o)
2.361 (1) Cl(1)-Ru-Cl(2) 91.38(4)
2.362 (1) CI(1)-Ru-N(1) 171.61(9)
2.122 (3) CI(2)-Ru-N(1) 92.20(9)
2.033 (3) Cl(1)-Ru-O(11) 93.44(9)
2.142 (3) Cl(2)-Ru-O(11) 89.22(9)
2.026 (3) N(1)-Ru-O(11) 79.0(1)
1.503 (5) CI(1)-Ru-N(2) 92.30(9)
1.502 (5) CI(2)-Ru-N(2) 172.03(8)
1.531 (6) N(1)-Ru-N(2) 85.1 (1)
1.523 (5) O(ll)-Ru-N(2) 97.6(1)
1.493 (5) Cl(1)-Ru-O(21) 89.69(8)
1.476 (5) C1(2)-Ru-O(21) 92.76(8)
1.521 (6) N(1)-Ru-O(21) 97.7(1)
1.260 (5) O(11)-Ru-O(21) 176.3(1)
1.245 (5) N(2)-Ru-O(21) 80.2(1)
1.510 (6) C(2)-C(1)-N(1) 111.6(3)
1.215 (5) C(1)-C(2)-C(3) 110.0(3)
1.314 (5) C(1)-C(2)-N(2) 109.2(3)
1.496 (5) C(3)-C(2)-N(2) 114.7(3)
1.481 (5) Ru-N(1)-C(1) 105.1 (2)
1.521 (5) Ru-N(1)-C(11) 105.7(2)
1.276 (4) C(1)-N(1)-C(11) 109.6(3)
1.239 (5) Ru-N(1)-C(13) 110.6(2)
1.518 (5) C(1)-N(1)-C(13) 112.3(3)
1.207 (5) C(11)-N(1)-C(13) 113.0(3)
1.313 (5) N(1)-C(11)-C(12) 109.5(3)
C(11)-C(12)-O(11) 117.9(3)
C(11)-C(12)-O(12) 118.5(4)
O(11)-C(12)-O(12) 123.6(4)
2.552(6) Ru-O(11)-C(12) 115.3(3)
2.650(5) N(1)-C(13)-C(14) 116.2(3)
3.230(4) C(13)-C(14)-O(13) 125.7(4)
2.793(5) C(13)-C(14)-O(14) 110.9(4)
2.582(6) O(13)-C(14)-O(14) 123.4(4)
2.520(5) Ru-N(2)-C(2) 105.2(2)
2.472(7) Ru-N(2)-C(21) 104.1 (2)
3.239(4) C(2)-N(2)-C(21) 109.5(3)
2.751 (6) Ru-N(2)-C(23) 109.5(2)
3.305(5) C(2)-N(2)-C(23) 114.9(3)
C(21)-N(2)-C(23) 112.8(3)
N(2)-C(21)-C(22) 110.3(3)
C(21 )-C(22)-O(21) 118.0(3)
C(21 )-C(22)-O(22) 120.1 (3)
O(21 )-C(22)-O(22) 121.9(4)
Ru-O(21)-C(22) 114.8(2)
N(2)-C(23)-C(24) 118.3(3)
C(23)-C(24)-O(23) 125.1 (4)
C(23)-C(24)-O(24) 110.6(3)
O(23)-C(24)-O(24) 124.2(4)
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Antitumor activity
The antitumor activity of the synthesized ruthenium complex has been evaluated against the
murine and human tumors mentioned in the experimental part of this paper. The results obtained are
reported in Table 5. The complex exhibits a noteworthy activity against Ehrlich ascitic tumor, with a
maximum T/C value of 460 correspopnding to a dose of 120 mg/Kg. The ruthenium drug presents an
important antitumor action against the murine leukemias L1210 and P388, it being the optimum dose
the same as in EAT case. The most important finding is the marked cytotoxic effect shown by the
ruthenium complex against the MX-1 human mammary tumor, even larger than in the case of DCTA-
Ru compound(9). Cures are complete in the EAT case with a long term survivors of 8/8 and appreciable
in the L1210 and P388 leukemias (LTS of 4/8 and 3/8, respectively). The complex is exceptionally well
tolerated and shows an absolute lack of nephrotoxicity and liver toxicity at all given doses. Moreover,
myelosuppression is not observed.
Table 5. Antitumor activity (T/C, %) of the complex [RuLCI2]H.4H20
Tumors
doses (mg/Kg) EAT L1210 P388 MX-1 M5076
10 180 110
25 360 130 125
60 410 210 150
120 460 190 160
250 130 110 125
13
10
125
130
100
pH
8,-
7-
6-
5-
3
equiv, alk/mol o compound
Figure 4: Potentiometric study of the complex [RuLCI2]H.4H20
Molar conductance (298K) changes from A 174 S cm2 (1 g-equiv, alkali)
to A 151 S cm2 (2 g-equiv, alkali)
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Potentiometric Study
Figure 4a corresponds to the potentiometric titration of a freshly prepared aqueous
solution of [RuLCI2] H.4H20. As can be seen, a sharp increase of pH is registered for the
consumption of 2 g-equiv, of alkali. The inflection point appears at pH 4.9. Moreover, a sudden
change in the electrical conductivity of the solution is observed at this point (Figure 4b), this fact
demonstrating the simultaneous neutralization of two free -COOH groups of the same strength.
These results evidence a tetradentate character for the PDTA, that contains two coordinated
carboxylate groups and two free carboxylic groups. The additional smooth inflection of the curve
observed at 3 g-equiv, of alkali may corresponds to the presence of a third weak acid hydrogen
atom somehow externally bonded to the complex. The pK value calculated from the curve is of
1.92, according to previous measurements on similar compounds (14).
All these facts have been checked by titration of the chlorine atoms present in the
substance. Dissolution of the compound in water leads to the slow substitution of one chlorine
atom from the inner sphere of the complex. If a freshly prepared solution is titrated with AgNO3,
0.60 g-equiv, of CI" are titrated whereas in a solution left to stand for 36 h, 1.43 g-equiv, of CI" were
found. If the position of the chlorine atom is taken by water, the substituted CI" must neutralize the
external H+. This fact has been confirmed by a new potentiometry, as observed in Figure 4c, in
which the second inflection has disappeared. Consequently, the coordinated PDTA contains two
free carboxylic groups even after the replacement of the chlorine atom.
Infrared spectroscopy
The isolated complex shows bands in the infrared spectra indicating the presence of both,
non-coordinated -COOH groups (1720 cm-1) and coordinated -CO0" groups (1610 cm-1).
Additional important vibrational modes are registered at 530 cm-1 (Ru-N bond) and by a split peak at
330 cm1 and 290 cm1, this fact indicating the presence of two chlorine atoms bonded to
ruthenium in cis positions. Other characteristic peaks of the complex appear in Table 4.
Table 4. IR data (cm-1) for the complex [RuLCI2]H.4H20
COOH COO" CH2 H20 Ru-N Ru-CI
(C---O) (C-H) hyd
1720 vs 1610 vs 2920 3510 vs 530 330
840 1380 Vas 2960 1630 5 295
vs and Vas: symmetric and asymmetric stretching vibrations;
,5: bending vibration.
Electronic and magnetic studies
The electronic spectra of aqueous solutions of the complex show three ’bands at 22830
cm-1 28570 cm-1 and 34480 cm-1. Extinction coefficients are larger than those calculated for Ru-
EDTA analogs. The registered absorptions may be attributed to the transitions 2A2g<--2T2g, 2Tl_<-_2T.. and 2E_ "’2T.. g .,.g g z.g"
ne magnetic Denawour of the substance is characteristic of a Curie-Weiss paramagnet in
the temperature range studied (80-298K). The magnetic moment changes from 1.76 #B (298K) to
1.89B (80K), which is as expected for one unpaired electron spin. These and other data (X-ray
Photoelectron Spectroscopy) are indicative of the +3 oxidation state for ruthenium, with a low-spin
4d5 configuration.
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